It is our mission to one day end the suffering caused by neurodegenerative diseases. Every day we strive for better therapies. We question the unquestioned, always in search of new solutions.
Amylyx is a pharmaceutical company based in Cambridge, Massachusetts, that is dedicated to the development of potential therapies for neurodegenerative diseases. We pursue unconventional approaches through lasting partnerships with industry leaders, scientists, doctors, and research organizations.
It all started as a curious dorm room inquiry at Brown University in 2013. After learning that neurodegenerative disease is the result of neuronal death, Amylyx co-founder Josh Cohen couldn't help but ask himself one simple question: "Why do neurons die?" It seemed like such an obvious starting point yet the solution was nowhere to be found.
After poring over an extensive supply of research, Josh and a classmate, co-founder Justin Klee, posed that question — and started the journey of uncovering the answers. Overcoming obstacle after obstacle, contracting with lab after lab, and formulating test after test, they eventually accumulated sufficient data to pursue the next steps.
In the years since, their partnership has transformed into Amylyx, a rapidly growing pharmaceutical company with the same curiosity and resilience as the day our company began. That simple question considered back in 2013 has led to a clinical reality — a new investigational product, AMX0035, currently in clinical development for the treatment of both amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
See the strides we've made since we were founded in 2013.
In this episode of Vital Science, our co-founders Justin and Josh revisit the company's humble beginnings.
Click to play.
People living with neurodegenerative diseases are our true north; we envision new possibilities, boldly seek untried approaches, and fearlessly innovate for them.
By asking the right questions, listening, and learning, we thrive in a culture of continuous improvement, driven by generously sharing knowledge, making each of us, and the company, better.
We can only understand someone's needs when we understand their journey. By deeply engaging with the neurodegenerative disease community and their care providers, we know what’s needed.
People living with neurodegenerative diseases always come first. There is no time to wait, and we have a responsibility to turn our most promising ideas into urgent action on their behalf.
When we genuinely care about the work we do and the people with whom we work, we make Amylyx a place where possibility could one day turn into reality.
Sandy, Person living with ALS
Gwen, Person living with ALS
Cali, ALS Caregiver
Greg, Person living with ALS
An error has occurred. Please refresh the page and retry.
The way we can move critical medicines forward is by doing so together — because true collaboration can change the course of a thought or an idea, or even the development of a therapy. Through strategic collaborations, patient-centric clinical trial design, and the sharing of ideas with open outreach, we can make a lasting impact in the neurodegenerative disease community.
People With Neurodegenerative Diseases
We've made some great strides in a short amount of time, but the work has just begun. If you'd like to join us in our mission, you can learn more about our culture and open positions below.
It's an honor to be a part of this tightly knit community. If you'd like to receive periodic updates and news about what's happening at Amylyx, click subscribe.